CELLAVISION AB (publ) Interim report for the period January 1 - June
30, 2009>
CELLAVISION AB (publ) Interim report for the period January 1 - June 30, 2009
(Thomson Reuters ONE) - Increased gross margin and next generation analyzer ready for launch* Net sales for the period amounted to SEK 42.7 million (41.3), an increase of 2 %. The second quarter accounted for SEK 20.7 million (22.8) of this amount.* The operating profit for the period was SEK 1.8 million (2.8) and for the second quarter SEK 1.0 million (1.5).* Earnings per share for the period amounted to SEK 0.06 (0.11).* Cash and cash equivalents were SEK 9.3 million (16.9) by the end of the quarter.* The new analyzer CellaVision® DM1200 was presented in Europe, and the first orders were taken.* CellaVision was awarded the SwedenBIO Award for its successes during 2008.* CellaVision's Japanese subsidiary received its first order.* CellaVision qualified for trade on the NASDAQ OMX First North Premier. CellaVision in summary (MSEK) Jan - June 2009 Jan - June 2008 Full year 2008 Net sales 42.7 41.3 100.4 Gross profit 30.9 25.8 63.5 Operating result 1.8 2.8 13.4 Net result 1.4 2.6 13.1 Cash flow -10.3 0.6 3.3CEO's comment"CellaVision's products are still receiving a great deal of attentionon our main markets. The hospital market is being increasinglyaffected by the global financial crisis and decisions to purchase aretaking longer, which is most apparent on the US market. Having saidthat, it is worth noting that we are still showing a positive resultdespite a financially unstable world market," says Yvonne Mårtensson,CEO of CellaVision."Our new product, the CellaVision DM1200 provides CellaVision with awider and stronger range of products, giving us a more competitiveedge. The product was shown in Europe for the first time during thisquarter. The analyzer was very well received and CellaVision hasalready taken its first orders from Sysmex in Europe. We are nowwaiting for the product to be ready for sale in the end of July, andthe next step will be to obtain the approvals needed to sell theCellaVision DM1200 on other markets. The development of this producthas demanded large resources during the period, which has contributedto the negative cash flow.""Our investments in our own sales organizations in Japan and NorthAmerica have resulted in the first Japanese order received from oneof Japan's largest laboratory chains as well as several importantorders in Canada. North America accounted for 54 % during theperiod."For more information please contact:Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail:yvonne.martensson(at)cellavision.comJohan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail:johan.wennerholm(at)cellavision.comDownload the report by pressing the link below.http://hugin.info/132164/R/1328931/313467.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
" alt="Rule 8.3 AXA IM UK LTD: VENTURE PRODUCTION PLC>">
" alt="A letter of intent regarding the new ownership structure of
Metsä-Botnia>">
Datum: 15.07.2009 - 12:19 Uhr
Sprache: Deutsch
News-ID 3587
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 361 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CELLAVISION AB (publ) Interim report for the period January 1 - June
30, 2009>"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
